Replies to post #4043 on Mountain High Stock Club

[EZ2]

GOOD morning!! ;-)

[EZ2]

Perhaps, a "peek under the tent" !


Concert Pharmaceuticals Starts Phase 1 Trial on Safety, Tolerability, Pharmacokinetics of its CTP-730 Drug

MIDNIGHT TRADER 7:07 AM ET 09/17/14

Symbol Last Price Change
CNCE 13.1 0 (0%)
CELG 92.57 0 (0%)
QUOTES AS OF 04:00:00 PM ET 09/16/2014

07:07 AM EDT, 09/17/2014 (MT Newswires) -- Concert Pharmaceuticals(CNCE) said it has initiated a phase 1 clinical trial that will study the safety, tolerability and pharmacokinetics of CTP-730 drug that is being developed together with Celgene Corporation(CELG) for the treatment of inflammatory diseases.

CNCE closed higher 3.5% on Tuesday. in the upper half of the 52-week range between $7.12 and $16.26. CELG also closed up 3.5% and then gave up 0.1% in after-hours trading, near the higher end of the 52-week range between $66.85 and $96.44.

Price: 13.10, Change: , Percent Change:

©http://www.mtnewswires.com © 2014 MT Newswires, a Division of MidnightTrader, Inc. All rights reserved.